{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T14:36:51Z","timestamp":1781620611198,"version":"3.54.5"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T00:00:00Z","timestamp":1772668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":39,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01DA052381"],"award-info":[{"award-number":["R01DA052381"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Community-based drug checking services have scaled up in response to the unregulated drug toxicity crisis across North America. We sought to assess the relationship between the detection of unexpected active drugs in a drug checking sample and subsequent engagement in risk reduction practices.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We used data from a cross-sectional study of people who used community-based drug checking services in British Columbia, Canada (March 2020\u2013July 2024). We constructed multivariable logistic regression models to examine the relationship between the detection of unexpected active drugs (i.e., compounds that have psychoactive properties) in samples brought for analysis (using combination Fourier-transform infrared spectroscopy and immunoassay strips) and engagement in subsequent risk reduction practices (e.g., dose reduction, disposal of the drug).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In total, 447 individuals were included: 174 (38.9%) reported detection of unexpected active drugs in their drug checking sample with the most common being benzodiazepines in expected opioid samples. The most common risk reduction behaviours were to dispose of the drug without using it (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200924) and taking a smaller dose (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200911). Through multivariable logistic regression, we found a positive association between detection of unexpected active drugs and engagement in risk reduction practices (adjusted odds ratio\u2009=\u20092.24; 95% confidence interval: 1.30\u20133.87).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Individuals who detected unexpected active drugs in their sample had higher odds of engaging in risk reduction practices. These findings highlight the potential of drug checking services as a harm reduction tool within a suite of services offered to combat the unpredictable and unregulated drug supply.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12954-025-01374-x","type":"journal-article","created":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T12:03:51Z","timestamp":1772712231000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Risk reduction behaviours following the detection of unexpected drugs through community drug checking: a cross-sectional study"],"prefix":"10.1186","volume":"23","author":[{"given":"Samuel","family":"Tobias","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cameron","family":"Grant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Lysyshyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perrine","family":"Roux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Kerr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianping","family":"Ti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,5]]},"reference":[{"key":"1374_CR1","doi-asserted-by":"publisher","first-page":"100240","DOI":"10.1016\/j.dadr.2024.100240","volume":"12","author":"RA Kleinman","year":"2024","unstructured":"Kleinman RA. Fentanyl, carfentanil and other fentanyl analogues in Canada\u2019s illicit opioid supply: a cross-sectional study. Drug Alcohol Depend Rep. 2024;12:100240. https:\/\/doi.org\/10.1016\/j.dadr.2024.100240.","journal-title":"Drug Alcohol Depend Rep"},{"key":"1374_CR2","doi-asserted-by":"publisher","first-page":"103933","DOI":"10.1016\/j.drugpo.2022.103933","volume":"111","author":"C Russell","year":"2023","unstructured":"Russell C, Law J, Bonn M, Rehm J, Ali F. The increase in benzodiazepine-laced drugs and related risks in canada: the urgent need for effective and sustainable solutions. Int J Drug Policy. 2023;111:103933. https:\/\/doi.org\/10.1016\/j.drugpo.2022.103933.","journal-title":"Int J Drug Policy"},{"key":"1374_CR3","doi-asserted-by":"publisher","first-page":"110985","DOI":"10.1016\/j.drugalcdep.2023.110985","volume":"252","author":"KD Wagner","year":"2023","unstructured":"Wagner KD, Fiuty P, Page K, et al. Prevalence of fentanyl in methamphetamine and cocaine samples collected by community-based drug checking services. Drug Alcohol Depend. 2023;252:110985. https:\/\/doi.org\/10.1016\/j.drugalcdep.2023.110985.","journal-title":"Drug Alcohol Depend"},{"key":"1374_CR4","unstructured":"Public Health Agency of Canada. Opioid- and stimulant-related harms in Canada. 2024. https:\/\/health-infobase.canada.ca\/substance-related-harms\/opioids-stimulants\/# .\u00a0Accessed 16 Jan 2025."},{"key":"1374_CR5","unstructured":"British Columbia Centre for Disease Control. Unregulated Drug Poisoning Emergency Dashboard [Dashboard]. http:\/\/www.bccdc.ca\/health-professionals\/data-reports\/substance-use-harm-reduction-dashboard .\u00a0Accessed 16 Jan 2025."},{"key":"1374_CR6","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s12954-023-00912-9","volume":"20","author":"M Ferguson","year":"2023","unstructured":"Ferguson M, Choisil P, Lamb J et al. Associations with experience of non-fatal opioid overdose in British Columbia, Canada: a repeated cross sectional survey study. Harm Reduct J. 2023;20:178. https:\/\/doi.org\/10.1186\/s12954-023-00912-9.","journal-title":"Harm Reduct J."},{"issue":"9","key":"1374_CR7","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1111\/add.14664","volume":"114","author":"MA Irvine","year":"2019","unstructured":"Irvine MA, Kuo M, Buxton JA, et al. Modelling the combined impact of interventions in averting deaths during a synthetic-opioid overdose epidemic. Addiction. 2019;114(9):1602\u201313. https:\/\/doi.org\/10.1111\/add.14664.","journal-title":"Addiction"},{"key":"1374_CR8","doi-asserted-by":"publisher","first-page":"109427","DOI":"10.1016\/j.drugalcdep.2022.109427","volume":"235","author":"A Larnder","year":"2022","unstructured":"Larnder A, Saatchi A, Borden SA, et al. Variability in the unregulated opioid market in the context of extreme rates of overdose. Drug Alcohol Depend. 2022;235:109427. https:\/\/doi.org\/10.1016\/j.drugalcdep.2022.109427.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"1374_CR9","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s12954-020-00454-4","volume":"17","author":"V Long","year":"2020","unstructured":"Long V, Arredondo J, Ti L, et al. Factors associated with drug checking service utilization among people who use drugs in a Canadian setting. Harm Reduct J. 2020;17(1):100. https:\/\/doi.org\/10.1186\/s12954-020-00454-4.","journal-title":"Harm Reduct J"},{"key":"1374_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drugalcdep.2019.01.0351","volume":"198","author":"G Bardwell","year":"2019","unstructured":"Bardwell G, Boyd J, Arredondo J, McNeil R, Kerr T. Trusting the source: the potential role of drug dealers in reducing drug-related harms via drug checking. Drug Alcohol Depend. 2019;198:1\u20136. https:\/\/doi.org\/10.1016\/j.drugalcdep.2019.01.0351.","journal-title":"Drug Alcohol Depend"},{"key":"1374_CR11","doi-asserted-by":"publisher","first-page":"112751","DOI":"10.1016\/j.drugalcdep.2025.112751","volume":"274","author":"H Esopenko","year":"2025","unstructured":"Esopenko H, Marshall BDL, Lysyshyn M, et al. Impact of having a regular drug dealer on obtaining drug checking results consistent with expectations during a drug toxicity crisis in a Canadian setting. Drug Alcohol Depend. 2025;274:112751. https:\/\/doi.org\/10.1016\/j.drugalcdep.2025.112751.","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"1374_CR12","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1111\/add.15734","volume":"117","author":"N Maghsoudi","year":"2022","unstructured":"Maghsoudi N, Tanguay J, Scarfone K, et al. Drug checking services for people who use drugs: a systematic review. Addiction. 2022;117(3):532\u201344. https:\/\/doi.org\/10.1111\/add.15734.","journal-title":"Addiction"},{"key":"1374_CR13","unstructured":"The Province of British Columbia. Drug checking. Help starts here. 2023. https:\/\/helpstartshere.gov.bc.ca\/substance-use\/harm-reduction\/drug-checking .\u00a0Accessed 17 Jan 2025."},{"key":"1374_CR14","doi-asserted-by":"publisher","first-page":"104903","DOI":"10.1016\/j.drugpo.2025.104903","volume":"143","author":"J Bird","year":"2025","unstructured":"Bird J, Tobias S, Grant C, et al. Sharing drug checking results in a Canadian setting: a multi-site analysis. Int J Drug Policy. 2025;143:104903. https:\/\/doi.org\/10.1016\/j.drugpo.2025.104903.","journal-title":"Int J Drug Policy"},{"key":"1374_CR15","doi-asserted-by":"publisher","first-page":"103270","DOI":"10.1016\/j.drugpo.2021.103270","volume":"95","author":"F Measham","year":"2021","unstructured":"Measham F, Turnbull G. Intentions, actions and outcomes: a follow up survey on harm reduction practices after using an English festival drug checking service. Int J Drug Policy. 2021;95:103270. https:\/\/doi.org\/10.1016\/j.drugpo.2021.103270.","journal-title":"Int J Drug Policy"},{"issue":"4","key":"1374_CR16","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1080\/09687637.2022.2072187","volume":"30","author":"H Valente","year":"2023","unstructured":"Valente H, Martins D, Pinto M, Fernandes L, Barratt MJ. A longitudinal study of behavioural outcomes following a visit to the boom festival 2018 drug checking service: individual and group level results. Drugs Educ Prev Policy. 2023;30(4):373\u201382. https:\/\/doi.org\/10.1080\/09687637.2022.2072187.","journal-title":"Drugs: Educ Prev Policy"},{"key":"1374_CR17","unstructured":"Knill A, Angelucci J, Tobias S, Matthews J, Ti L. Trends in drug checking results across British Columbia. January to December 2022. British Columbia Centre on Substance Use; 2023. https:\/\/drugcheckingbc.ca\/wp-content\/uploads\/sites\/2\/2023\/08\/BCCSU_BCs_Annual_Drug_Checking_Report_2022_final.pdf .\u00a0Accessed 5 Feb\u00a0 2025."},{"key":"1374_CR18","unstructured":"BC Centre on Substance Use. BCCSU DrugSense Dashboard [Dashboard]. https:\/\/drugcheckingbc.ca\/dashboard\/ . Accessed 6 Oct 2025."},{"issue":"4","key":"1374_CR19","first-page":"177","volume":"64","author":"R Purssell","year":"2021","unstructured":"Purssell R, Buxton JA, Godwin J, Moe J. Potent sedatives in opioids in BC: implications for resuscitation, and benzodiazepine and etizolam withdrawal. Br Columbia Med J. 2021;64(4):177\u20138.","journal-title":"Br Columbia Med J"},{"issue":"1","key":"1374_CR20","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s12954-024-01014-w","volume":"21","author":"L Moran","year":"2024","unstructured":"Moran L, Ondocsin J, Outram S, et al. How do we understand the value of drug checking as a component of harm reduction services? A qualitative exploration of client and provider perspectives. Harm Reduct J. 2024;21(1):92. https:\/\/doi.org\/10.1186\/s12954-024-01014-w.","journal-title":"Harm Reduct J"},{"key":"1374_CR21","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.drugalcdep.2018.10.017","volume":"194","author":"JL Glick","year":"2019","unstructured":"Glick JL, Christensen T, Park JN, McKenzie M, Green TC, Sherman SG. Stakeholder perspectives on implementing fentanyl drug checking: results from a multi-site study. Drug Alcohol Depend. 2019;194:527\u201332. https:\/\/doi.org\/10.1016\/j.drugalcdep.2018.10.017.","journal-title":"Drug Alcohol Depend"},{"key":"1374_CR22","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.drugpo.2019.07.007","volume":"73","author":"H Valente","year":"2019","unstructured":"Valente H, Martins D, Carvalho H, et al. Evaluation of a drug checking service at a large scale electronic music festival in Portugal. Int J Drug Policy. 2019;73:88\u201395. https:\/\/doi.org\/10.1016\/j.drugpo.2019.07.007.","journal-title":"Int J Drug Policy"},{"key":"1374_CR23","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.drugpo.2018.11.001","volume":"67","author":"FC Measham","year":"2019","unstructured":"Measham FC. Drug safety testing, disposals and dealing in an English field: exploring the operational and behavioural outcomes of the UK\u2019s first onsite \u2018drug checking\u2019 service. Int J Drug Policy. 2019;67:102\u20137. https:\/\/doi.org\/10.1016\/j.drugpo.2018.11.001.","journal-title":"Int J Drug Policy"},{"issue":"3","key":"1374_CR24","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1111\/bcp.14231","volume":"86","author":"F Measham","year":"2020","unstructured":"Measham F. City checking: piloting the UK\u2019s first community-based drug safety testing (drug checking) service in 2 City centres. Br J Clin Pharmacol. 2020;86(3):420\u20138. https:\/\/doi.org\/10.1111\/bcp.14231.","journal-title":"Br J Clin Pharmacol"},{"key":"1374_CR25","doi-asserted-by":"publisher","first-page":"104290","DOI":"10.1016\/j.drugpo.2023.104290","volume":"123","author":"S Tobias","year":"2024","unstructured":"Tobias S, Ferguson M, Palis H, et al. Motivators of and barriers to drug checking engagement in British Columbia, Canada: findings from a cross-sectional study. Int J Drug Policy. 2024;123:104290. https:\/\/doi.org\/10.1016\/j.drugpo.2023.104290.","journal-title":"Int J Drug Policy"},{"key":"1374_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/09687637.2024.2412995","volume":"15","author":"M Verdenik","year":"2024","unstructured":"Verdenik M, Rolando S, Sande M. I will not use it because the results are bad\u2019 \u2013 understanding the influence of the drug checking service on changing consumption behavior. Drugs Educ Prev Policy. 2024;15:1\u20138. https:\/\/doi.org\/10.1080\/09687637.2024.2412995.","journal-title":"Drugs Educ Prev Policy"},{"key":"1374_CR27","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.drugpo.2018.08.007","volume":"63","author":"NC Peiper","year":"2019","unstructured":"Peiper NC, Clarke SD, Vincent LB, Ciccarone D, Kral AH, Zibbell JE. Fentanyl test strips as an opioid overdose prevention strategy: findings from a syringe services program in the southeastern United States. Int J Drug Policy. 2019;63:122\u20138. https:\/\/doi.org\/10.1016\/j.drugpo.2018.08.007.","journal-title":"Int J Drug Policy"},{"issue":"1","key":"1374_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/109019818401100101","volume":"11","author":"NK Janz","year":"1984","unstructured":"Janz NK, Becker MH. The health belief model: a decade later. Health Educ Q. 1984;11(1):1\u201347. https:\/\/doi.org\/10.1177\/109019818401100101.","journal-title":"Health Educ Q"},{"key":"1374_CR29","unstructured":"Alyafei A, Easton-Carr R. The health belief model of behavior change. StatPearls; 2024. Accessed 15 Apr 2025. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK606120\/"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-025-01374-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-025-01374-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-025-01374-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T11:50:13Z","timestamp":1776081013000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12954-025-01374-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,5]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1374"],"URL":"https:\/\/doi.org\/10.1186\/s12954-025-01374-x","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,5]]},"assertion":[{"value":"4 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Research ethics approval was obtained from the Providence Health Care\/University of British Columbia Research Ethics Board (certificate H17-03158). All participants in the study provided informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Evan Wood is a physician who works for Vancouver Coastal Health in the area of withdrawal management and undertakes work in the area of occupational addiction medicine. Dr. Wood is also a professor of medicine based at the University of British Columbia (UBC), a position supported by a Canadian Institutes of Health Research (CIHR) Tier 1 Canada Research Chair, and has received salary support from an R01 from the US National Institute on Drug Abuse, paid to UBC. Dr. Wood\u2019s research lab is further supported by CIHR grants to the Canadian Research Initiative in Substance Misuse. Dr. Wood has also undertaken consulting work in legal matters related to substance use disorders and for a mental health company called Numinus Wellness, where Dr. Wood is former chief medical officer; Dr. Wood has also received compensation in the form of equity in Numinus. Dr. Wood reports receiving honoraria for non-industry related academic lectures and conference presentations. Dr. Wood has also received payment for expert reports and expert testimony in legal matters pertaining to substance use disorder, including from the Canadian Medical Protective Association and from trade unions representing workers with possible substance use disorder. Dr. Wood has received travel support from the CIHR.All other authors have no conflicts of interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"72"}}